Clinical Trial of Recombinant Adenovirus Type 5 AIDS Vaccine
Phase I Clinical Trial of Recombinant Adenovirus Type 5 Therapeutic AIDS Vaccine Expressing Gag
Sponsor: Beijing Ditan Hospital
Listed as NCT02762045, this PHASE1 trial focuses on Acquired Immunodeficiency Syndrome and remains ongoing. Sponsored by Beijing Ditan Hospital, it has been updated 6 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Apr 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beijing Ditan Hospital
- Centers for Disease Control and Prevention, China
- National Institutes for Food and Drug Control, China
For direct contact, visit the study record on ClinicalTrials.gov .